MedTrace Logo

PPD™ CorEvitas™ Psoriasis (PSO) Early Treatment Response Non-Interventional Study

NCT07648602 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2500

Last updated 2026-06-15

No results posted yet for this study

Summary

This is a 24-week prospective, single-arm cohort, study of patients initiating advanced therapy for the treatment of moderate-to-severe plaque PSO. Eligible patients must be willing to be seen in-person by their treating physician for a Baseline visit (with first dose of the advanced therapy occurring within 14 days), and at 16 (+/- 5 days) and 24 weeks (+14 days) calculated based on date of first dose of the advanced therapy and must provide informed consent prior to enrolling in the study or completing study-specific questionnaires or procedures. Data will be collected from both subjects and their treating dermatology provider at predetermined scheduled intervals (Baseline, Week 16 and Week 24) using a structured and standardized data collection tool.

Conditions

Interventions

OTHER

Observational (Non-Interventional) Registry

This is an observational (non-interventional) registry

Sponsors & Collaborators

  • CorEvitas

    lead NETWORK

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-06-01
Primary Completion
2036-12-31
Completion
2036-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07648602 on ClinicalTrials.gov